ABIVAX Société Anonyme (AAVXF)
USD 11.05
(0.0%)
USD 11.05
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 131.05 Million EUR | 102.71% |
| 2022 | 64.65 Million EUR | -13.51% |
| 2021 | 74.75 Million EUR | 39.99% |
| 2020 | 53.39 Million EUR | 61.15% |
| 2019 | 33.13 Million EUR | 70.87% |
| 2018 | 19.39 Million EUR | 244.15% |
| 2017 | 5.63 Million EUR | 45.23% |
| 2016 | 3.88 Million EUR | -13.78% |
| 2015 | 4.5 Million EUR | 11.64% |
| 2014 | 4.03 Million EUR | -9.29% |
| 2013 | 4.44 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 158.02 Million EUR | 0.0% |
| 2024 Q1 | 158.02 Million EUR | 20.58% |
| 2023 FY | 131.05 Million EUR | 102.71% |
| 2023 Q3 | 131.05 Million EUR | 44.66% |
| 2023 Q1 | 90.59 Million EUR | 40.12% |
| 2023 Q4 | 131.05 Million EUR | 0.0% |
| 2023 Q2 | 90.59 Million EUR | 0.0% |
| 2022 Q1 | 65.56 Million EUR | -12.3% |
| 2022 Q4 | 64.65 Million EUR | -5.42% |
| 2022 Q3 | 68.35 Million EUR | 4.26% |
| 2022 Q2 | 65.56 Million EUR | 0.0% |
| 2022 FY | 64.65 Million EUR | -13.51% |
| 2021 Q2 | 52.72 Million EUR | 0.0% |
| 2021 Q3 | 83.29 Million EUR | 58.0% |
| 2021 Q4 | 74.75 Million EUR | -10.26% |
| 2021 FY | 74.75 Million EUR | 39.99% |
| 2021 Q1 | 52.72 Million EUR | -1.27% |
| 2020 Q1 | 40.2 Million EUR | 21.34% |
| 2020 Q2 | 40.2 Million EUR | 0.0% |
| 2020 Q3 | 53.39 Million EUR | 32.81% |
| 2020 Q4 | 53.39 Million EUR | 0.0% |
| 2020 FY | 53.39 Million EUR | 61.15% |
| 2019 Q4 | 33.13 Million EUR | 0.0% |
| 2019 Q1 | 33.68 Million EUR | 73.7% |
| 2019 Q3 | 33.13 Million EUR | -1.63% |
| 2019 FY | 33.13 Million EUR | 70.87% |
| 2019 Q2 | 33.68 Million EUR | 0.0% |
| 2018 Q3 | 19.39 Million EUR | 291.09% |
| 2018 FY | 19.39 Million EUR | 244.15% |
| 2018 Q2 | 4.95 Million EUR | 0.57% |
| 2018 Q1 | 4.93 Million EUR | -12.49% |
| 2018 Q4 | 19.39 Million EUR | -0.01% |
| 2017 Q4 | 5.63 Million EUR | 3.68% |
| 2017 Q3 | 5.43 Million EUR | 35.2% |
| 2017 Q2 | 4.02 Million EUR | 0.0% |
| 2017 Q1 | 4.01 Million EUR | 3.61% |
| 2017 FY | 5.63 Million EUR | 45.23% |
| 2016 Q2 | 3.79 Million EUR | 0.0% |
| 2016 Q4 | 3.88 Million EUR | 0.0% |
| 2016 Q3 | 3.88 Million EUR | 2.32% |
| 2016 Q1 | 3.79 Million EUR | -15.73% |
| 2016 FY | 3.88 Million EUR | -13.78% |
| 2015 FY | 4.5 Million EUR | 11.64% |
| 2015 Q3 | 4.53 Million EUR | -48.65% |
| 2015 Q4 | 4.5 Million EUR | -0.66% |
| 2015 Q1 | 8.82 Million EUR | 118.83% |
| 2015 Q2 | 8.82 Million EUR | 0.0% |
| 2014 Q4 | 4.03 Million EUR | 0.02% |
| 2014 Q3 | 4.03 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 4.03 Million EUR | -9.29% |
| 2013 FY | 4.44 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -145.853% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1267.686% |
| SQZ Biotechnologies Company | 50.03 Million USD | -161.9% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -80.834% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -122.069% |
| Mesoblast Limited | 188.44 Million USD | 30.456% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3302.689% |
| Genus plc | 485 Million USD | 72.979% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2143.034% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -5108.065% |
| Marizyme, Inc. | 26.67 Million USD | -391.278% |
| ContraFect Corporation | 32.53 Million USD | -302.853% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3348.737% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -6514.418% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3323.826% |
| Intellipharmaceutics International Inc. | 12 Million USD | -991.303% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1012.666% |
| MultiCell Technologies, Inc. | 1617.67 USD | -8101181.411% |
| Accustem Sciences Inc. | 1.07 Million USD | -12043.001% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -69.281% |
| EV Biologics, Inc. | 2.11 Million USD | -6096.11% |
| Q BioMed Inc. | 8.13 Million USD | -1511.373% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -58.018% |
| Neon Bloom, Inc. | 1.22 Million USD | -10587.54% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2446.66% |
| Biomind Labs Inc. | 1.49 Million USD | -8644.892% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 46.306% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -612.107% |
| Skye Bioscience, Inc. | 14.07 Million USD | -831.281% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -6419.578% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -92128.438% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1284.461% |
| IMV Inc. | 37.93 Million USD | -245.485% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -65062.393% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2180.823% |
| GB Sciences, Inc. | 5.41 Million USD | -2319.024% |
| Alpha Cognition Inc. | 7.16 Million USD | -1729.116% |
| HST Global, Inc. | 593.59 Thousand USD | -21977.753% |
| CSL Limited | 18.62 Billion USD | 99.296% |
| Halberd Corporation | 728.71 Thousand USD | -17883.887% |
| Enzolytics Inc. | 365.26 Million USD | 64.122% |
| Resverlogix Corp. | 67.39 Million USD | -94.451% |
| Affymax, Inc. | 8.87 Million USD | -1377.308% |
| SYBLEU INC | 681.41 Thousand USD | -19132.389% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -15525.015% |
| argenx SE | 444.95 Million USD | 70.547% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -74.923% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -7545.974% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1000.99% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3475.611% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3181.431% |
| Zenith Capital Corp. | 27.56 Thousand USD | -475260.002% |
| Genscript Biotech Corporation | 1.32 Billion USD | 90.116% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -54812.97% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3409.407% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -19148.745% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -10.385% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1349.339% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -195707.496% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -9039.798% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -160.727% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -4732.941% |
| BioStem Technologies, Inc. | 15.9 Million USD | -723.985% |
| ONE Bio Corp. | 27.49 Million USD | -376.625% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -28101.481% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -477616.615% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -10307.618% |
| Agentix Corp. | 2.51 Million USD | -5120.041% |
| LadRx Corporation | 2.2 Million USD | -5855.48% |
| Cell Source, Inc. | 15.8 Million USD | -729.091% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -293107.444% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2301.268% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2301.268% |
| NovAccess Global Inc. | 7.86 Million USD | -1567.173% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -429.588% |
| Itoco Inc. | 1.65 Million USD | -7827.406% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -6287.904% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2066.507% |
| Kadimastem Ltd | 3.5 Million USD | -3639.143% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -30986.8% |
| CytoDyn Inc. | 127.89 Million USD | -2.469% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -313429.029% |
| Mobile Lads Corp. | 1.31 Million USD | -9877.335% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -8266.568% |
| Qrons Inc. | 1.48 Million USD | -8703.04% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1086.497% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -16103.384% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2400.038% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2047.723% |
| International Stem Cell Corporation | 5.27 Million USD | -2383.456% |
| Bioxytran, Inc. | 3.24 Million USD | -3932.99% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -20841.214% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2738.39% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -219.67% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -488.601% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -6370.467% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2292.333% |
| Neutra Corp. | 973.52 Thousand USD | -13361.54% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -351.67% |
| PureTech Health plc | 125.58 Million USD | -4.355% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3388.093% |
| IXICO plc | 1.9 Million USD | -6796.414% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -538.375% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -26.836% |
| CSL Limited | 18.62 Billion USD | 99.296% |
| Cellectis S.A. | 249.36 Million USD | 47.447% |